Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
Financial Results:
Sun Pharmaceuticals Industries Ltd reported Revenues for Q2FY24 of ₹12,192.00 Crores up from ₹10,952.00 Crore year on year, a rise of 11.32%.
Total Expenses for Q2FY24 of ₹9,695.00 Crores up from ₹8,625.00 Crores year on year, a rise of 12.41%.
Consolidated Net Profit of ₹2,385.00 Crores up 5.72% from ₹2,256.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹9.90, up 4.98% from ₹9.43 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.